Treatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution

Simple item page
atmire.migration.oldid5014
dc.contributor.advisorBebb, Gwyn
dc.contributor.advisorKopciuk, Karen
dc.contributor.authorTudor, Roxana
dc.contributor.committeememberBrenner, Darren
dc.contributor.committeememberTremblay, Alain
dc.contributor.committeememberMacEachern, Paul
dc.date.accessioned2016-10-04T20:02:34Z
dc.date.available2016-10-04T20:02:34Z
dc.date.issued2016
dc.date.submitted2016en
dc.description.abstractOptimal treatment beyond disease-progression (PD) in non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations, treated with tyrosine kinase inhibitors (TKIs), is not well-defined. In this retrospective study, the following aims were set out: 1) compare outcomes and profile of EGFRmut+ NSCLC patients to large cohorts of lung-cancer patients from the Glans-Look lung cancer database -GLD; 2) examine the frequency of continuing TKI treatment beyond PD in EGFRmut+ patients; 3) examine overall survival (OS) and post-progression survival (PPS) according to clinicopathological characteristics and; 4) propose a new PD-scoring model to help guide subsequent treatment formulation. Compared to the GLD-NSCLC cohort without systemic chemotherapy, EGFRmut+ patients were more likely to be younger, female and Asian. Further, continuing TKI treatment beyond PD was associated with improved OS and PPS vs. discontinuation of TKI. A non-independent relationship between EGFRmutation type and smoking history was identified.en_US
dc.identifier.citationTudor, R. (2016). Treatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/28522en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/28522
dc.identifier.urihttp://hdl.handle.net/11023/3403
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectOncology
dc.subject.classificationEGFRmut+en_US
dc.subject.classificationPDen_US
dc.subject.classificationTKIen_US
dc.titleTreatment at Disease-progression in EGFR-mutated NSCLC Patients: Results from a single Canadian Institution
dc.typemaster thesis
thesis.degree.disciplineMedical Science
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations